[{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Merck Group","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Children\u2019s Oncology Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Children\u2019s Oncology Group","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Children\u2019s Oncology Group"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Belantamab Mafodotin","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elranatamab","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat HBr","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Seagen"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ABBV-383","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat HBr","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Applied BioMath","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat HBr","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied BioMath \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat HBr","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase III","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat HBr","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Elranatamab","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elranatamab","moa":"||Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Nam Bui","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Nam Bui","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nam Bui \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nam Bui \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Hellenic Society of Hematology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hellenic Society of Hematology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Hellenic Society of Hematology \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Hellenic Society of Hematology \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpringWorks Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"SpringWorks Therapeutics \/ Precision BioSciences"}]
Find Clinical Drug Pipeline Developments & Deals for Nirogacestat
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
